| Literature DB >> 35915180 |
Chia-Chen Liu1, Jing Zhao2, Yuan Fu2, Yasuteru Inoue2, Yingxue Ren3, Yuanxin Chen2, Sydney V Doss2, Francis Shue2, Suren Jeevaratnam2, Ligia Bastea4, Na Wang2, Yuka A Martens2, Wenhui Qiao2, Minghui Wang4, Na Zhao2, Lin Jia2, Yu Yamazaki2, Akari Yamazaki2, Cassandra L Rosenberg2, Zhen Wang5, Dehui Kong6, Zonghua Li2, Lindsey A Kuchenbecker2, Zachary A Trottier2, Lindsey Felton2, Justin Rogers2, Zachary S Quicksall2, Cynthia Linares2, Joshua Knight2, Yixing Chen2, Aishe Kurti2, Takahisa Kanekiyo2, John D Fryer2, Yan W Asmann3, Peter Storz4, Xusheng Wang6, Junmin Peng5, Bin Zhang7, Betty Y S Kim8, Guojun Bu9.
Abstract
The ε4 allele of the apolipoprotein E (APOE) gene, a genetic risk factor for Alzheimer's disease, is abundantly expressed in both the brain and periphery. Here, we present evidence that peripheral apoE isoforms, separated from those in the brain by the blood-brain barrier, differentially impact Alzheimer's disease pathogenesis and cognition. To evaluate the function of peripheral apoE, we developed conditional mouse models expressing human APOE3 or APOE4 in the liver with no detectable apoE in the brain. Liver-expressed apoE4 compromised synaptic plasticity and cognition by impairing cerebrovascular functions. Plasma proteome profiling revealed apoE isoform-dependent functional pathways highlighting cell adhesion, lipoprotein metabolism and complement activation. ApoE3 plasma from young mice improved cognition and reduced vessel-associated gliosis when transfused into aged mice, whereas apoE4 compromised the beneficial effects of young plasma. A human induced pluripotent stem cell-derived endothelial cell model recapitulated the plasma apoE isoform-specific effect on endothelial integrity, further supporting a vascular-related mechanism. Upon breeding with amyloid model mice, liver-expressed apoE4 exacerbated brain amyloid pathology, whereas apoE3 reduced it. Our findings demonstrate pathogenic effects of peripheral apoE4, providing a strong rationale for targeting peripheral apoE to treat Alzheimer's disease.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35915180 DOI: 10.1038/s41593-022-01127-0
Source DB: PubMed Journal: Nat Neurosci ISSN: 1097-6256 Impact factor: 28.771